<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01212276</url>
  </required_header>
  <id_info>
    <org_study_id>MORAb-028-001</org_study_id>
    <nct_id>NCT01212276</nct_id>
  </id_info>
  <brief_title>A Safety and MORAb-028 Dose Determination Study in Subjects With Metastatic Melanoma</brief_title>
  <official_title>A Phase 1 Study of the Safety, Tolerability, Pharmacokinetics and Radiologic Distribution of Ascending Single-Dose Radiolabeled MORAb-028 in Subjects With Metastatic Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Morphotek</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Morphotek</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate whether therapy with MORAb-028 is safe, effective,
      and to determine the appropriate dose of MORAb-028 in the treatment of metastatic melanoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Melanoma is a serious form of skin cancer. If untreated, the melanoma can spread beyond the
      original affected tissue and invade distant tissue and organs. Treatment for metastatic
      melanoma includes medical treatments (chemotherapy or immunotherapy), surgery, or radiation
      therapy. MORAb-028 is a recombinant human immunoglobulin M (IgM) monoclonal antibody that
      recognizes a cell surface diacyl ganglioside named disialoganglioside (GD2). GD2 is
      overexpressed in tumors of neuro-ectodermal origin such as melanomas, neuroblastomas,
      small-cell lung carcinomas, and many sarcomas, while absent in most normal tissues. GD2
      expression has been demonstrated in human melanoma and small cell lung cancer by thin layer
      chromatography and radiolabeled anti-GD2 antibody detection. It is hypothesized that one mode
      of action of MORAb-028 is complement-dependent cytotoxicity. Complement-dependent
      cytotoxicity is a mechanism for killing tumor cells in which an antibody bound to the target
      cell surface fixes complement, which results in assembly of the complement membrane attack
      complex that punches holes in the target cell membrane resulting in subsequent cell lysis.
      IgMs strongly bind to C1Q and robustly activate complement-dependent cytotoxicity. MORAb-028
      is being developed as a potential therapy for GD2-positive tumors.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Sponsor terminated protocol
  </why_stopped>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of single dose radio labeled MORAb-028 in subjects with metastatic melanoma</measure>
    <time_frame>Daily for 7 days followed by weekly for 2 weeks, then biweekly for 4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Radiologic distribution of a single i.v. infusion of MORAb-028</measure>
    <time_frame>Daily for 1 week post study drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters of labeled and unlabeled MORAb-028</measure>
    <time_frame>Daily for 7 days followed by weekly for 2 weeks, then biweekly for 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of human antihuman antibody formation</measure>
    <time_frame>Week 2 and Week 8</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Metastatic Melanoma</condition>
  <condition>Malignant Metastatic Melanoma</condition>
  <condition>Advanced Melanoma</condition>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MORAb-028 0.1 mg/kg intravenous</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MORAb-028 0.2 mg/kg intravenous</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MORAb-028 0.5 mg/kg intravenous</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MORAb-028 1.0 mg/kg intravenous</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MORAb-028</intervention_name>
    <description>Cohort 1: 0.1 mg/kg IV on study day 1 only Cohort 2: 0.2 mg/kg IV on study day 1 only Cohort 3: 0.5 mg/kg IV on study day 1 only Cohort 4: 1.0 mg/kg IV on study day 1 only</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Measurable metastatic melanoma that has failed standard therapy

          -  Males and females greater than or equal to 18 years of age

          -  Life expectancy of greater than or equal to 3 months

        Exclusion Criteria:

          -  Significant cardiovascular impairment

          -  Clinically significant illness, medical condition, surgical history, or laboratory
             abnormality that could affect the safety of the subject or negatively impact the study
             results

          -  Chemotherapy, radiotherapy, or immunotherapy within 3 weeks prior to administration to
             MORAb-028
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christina Coughlin, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Morphotek</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jorge Carrasquillo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10022</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 29, 2010</study_first_submitted>
  <study_first_submitted_qc>September 29, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2010</study_first_posted>
  <last_update_submitted>July 15, 2014</last_update_submitted>
  <last_update_submitted_qc>July 15, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 16, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

